Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug

Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug

Thumbnail Image
Download
Name

Miller_Tumour-associated.pdf

Size

20.56 MB

Format

Adobe PDF

Checksum (MD5)

92e5970ed83729d4d726f134e2da92dc

Author(s)
Miller, Miles Aaron
•
Zheng, Yao-Rong
•
Gadde, Suresh
•
Pfirschke, Christina
•
Zope, Harshal
•
Engblom, Camilla
•
Kohler, Rainer H.
•
Iwamoto, Yoshiko
•
Yang, Katherine S.
•
Askevold, Bjorn
more
Date Issued
October 2015
Journal
Nature Communications
Publisher
Nature Publishing Group
Citation
Miller, Miles A., Yao-Rong Zheng, Suresh Gadde, Christina Pfirschke, Harshal Zope, Camilla Engblom, Rainer H. Kohler, et al. “Tumour-Associated Macrophages Act as a Slow-Release Reservoir of Nano-Therapeutic Pt(IV) Pro-Drug.” Nat Comms 6 (October 27, 2015): 8692. © 2015 Macmillan Publishers Limited
Version
Final published version
Abstract
Therapeutic nanoparticles (TNPs) aim to deliver drugs more safely and effectively to cancers, yet clinical results have been unpredictable owing to limited in vivo understanding. Here we use single-cell imaging of intratumoral TNP pharmacokinetics and pharmacodynamics to better comprehend their heterogeneous behaviour. Model TNPs comprising a fluorescent platinum(IV) pro-drug and a clinically tested polymer platform (PLGA-b-PEG) promote long drug circulation and alter accumulation by directing cellular uptake toward tumour-associated macrophages (TAMs). Simultaneous imaging of TNP vehicle, its drug payload and single-cell DNA damage response reveals that TAMs serve as a local drug depot that accumulates significant vehicle from which DNA-damaging Pt payload gradually releases to neighbouring tumour cells. Correspondingly, TAM depletion reduces intratumoral TNP accumulation and efficacy. Thus, nanotherapeutics co-opt TAMs for drug delivery, which has implications for TNP design and for selecting patients into trials.
MIT Department
Massachusetts Institute of Technology. Department of Chemistry
Terms of Use
Creative Commons Attribution
http://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/100507
DOI of Published Version
https://doi.org/10.1038/ncomms9692
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.